<DOC>
	<DOCNO>NCT00622869</DOCNO>
	<brief_summary>This trial design address important issue impact recipient liver allografts well clinician , ie , renal function , reduction discontinuation tacrolimus early post-transplantation , progression rate fibrosis hepatitis C virus ( HCV ) positive patient .</brief_summary>
	<brief_title>Efficacy Safety Concentration-controlled Everolimus Eliminate Reduce Tacrolimus Compared Tacrolimus de Novo Liver Transplant Recipients</brief_title>
	<detailed_description>This 24-month study consist screening period , baseline period ( 3 7 day post-transplantation ) follow run-in period end day randomization 30 day ( ± 5 day ) post-transplantation . Patients screen eligibility prior liver transplantation . Patients undergone successful liver transplantation initiate tacrolimus-based regimen include corticosteroid enter baseline period ( 3 7 day post-transplantation ) . At 30 ( ± 5 ) day post-transplantation , patient meet additional randomization inclusion/exclusion criterion randomize study .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Ability willingness provide write informed consent adhere study regimen . Recipients 1870 year age primary liver transplant decease donor . Recipients initiate immunosuppressive regimen contain corticosteroid tacrolimus , 37 day posttransplantation . Confirmed recipient hepatitis C virus ( HCV ) status Screening ( either antibody PCR ( polymerase chain reaction ) . Allograft function acceptable level time randomization define protocol specific laboratory value . Abbreviated Modification Diet Renal Disease estimate glomerular filtration rate ( MDRD eGFR ) ≥ 30 mL/min/1.73m2 . Results obtain within 5 day prior randomization acceptable , however , sooner Day 25 posttransplantation . Verification least 1 tacrolimus trough level ≥ 8 ng/mL week prior randomization . Investigators make adjustment tacrolimus dose continue target trough level 8 ng/mL prior randomization . Exclusion Criteria Patients recipients multiple solid organ islet cell tissue transplant , previously receive organ tissue transplant . Patients combine liverkidney transplant . Recipients liver living donor , split liver . History malignancy organ system within past 5 year whether evidence local recurrence metastasis , nonmetastatic basal squamous cell carcinoma skin , HCC ( hepatocellular carcinoma ) ( see next criterion ) . Hepatocellular carcinoma fulfill Milan criterion ( 1 nodule ≤ 5 cm , 23 nodule &lt; 3 cm ) time transplantation per explant histology recipient liver . Any use antibody induction therapy . Patients know hypersensitivity drug use study class , excipients . Patients recipient ABO incompatible transplant graft . Recipients organs donor test positive Hepatitis B surface antigen HIV exclude . Patients surgical medical condition , opinion investigator , might significantly alter absorption , distribution , metabolism excretion study drug . Women childbearing potential ( WOCBP ) . Patients history coagulopathy medical condition require longterm anticoagulation would preclude liver biopsy transplantation . ( Low dose aspirin treatment interruption chronic anticoagulant allow ) . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>calcineurin inhibitor</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>renal function</keyword>
	<keyword>MDRD formula</keyword>
	<keyword>progression fibrosis</keyword>
</DOC>